Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-5,208
Closed -$1.45M 114
2025
Q2
$1.45M Buy
5,208
+285
+6% +$80.7K 0.43% 76
2025
Q1
$1.53M Buy
4,923
+336
+7% +$99.2K 0.56% 67
2024
Q4
$1.2M Sell
4,587
-218
-5% -$64.7K 0.43% 82
2024
Q3
$1.55M Buy
4,805
+242
+5% +$79.2K 0.57% 71
2024
Q2
$1.43M Sell
4,563
-773
-14% -$227K 0.59% 66
2024
Q1
$1.52M Buy
+5,336
New +$1.56M 0.66% 62
2022
Q2
Sell
-40
Closed -$10K 114
2022
Q1
$10K Hold
40
0.01% 220
2021
Q4
$9K Sell
40
-511
-93% -$108K 0.01% 205
2021
Q3
$117K Sell
551
-2,748
-83% -$632K 0.09% 105
2021
Q2
$804K Sell
3,299
-18
-0.5% -$4.43K 0.62% 65
2021
Q1
$825K Buy
+3,317
New +$791K 0.76% 52

Other funds holding AMGN

Alaethes Wealth's AMGN Position: Q3 2025 in Review

Alaethes Wealth sold out of Amgen (AMGN) in Q3 2025, closing a stake of 5,208 shares — an estimated $1.45M sold.

Alaethes Wealth first reported a position in AMGN in Q1 2021 and held it in 11 quarters. The position peaked at $1.55M in Q3 2024. 2,819 funds tracked by Wall St. Rank hold AMGN as of Q3 2025.

  • Alaethes Wealth reported no remaining Amgen position as of Q3 2025 after selling out during the quarter.
  • Alaethes Wealth sold 5,208 Amgen shares in Q3 2025, an estimated $1.45M.
  • Alaethes Wealth first reported a position in Amgen in Q1 2021 and held it in 11 quarters.
  • Alaethes Wealth's Amgen position peaked at $1.55M in Q3 2024.
  • 2,819 funds tracked by Wall St. Rank held Amgen as of Q3 2025.

Based on Alaethes Wealth's 13F filing for Q3 2025, filed 13 Nov 2025.